<DOC>
	<DOCNO>NCT00378105</DOCNO>
	<brief_summary>The purpose study determine safety efficacy bortezomib , lenalidomide dexamethasone combination patient newly diagnose multiple myeloma . We look high dose combination give safely see well work combination newly diagnose patient .</brief_summary>
	<brief_title>Bortezomib , Lenalidomide Dexamethasone Combination Therapy Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description>- The safe dose dexamethasone already know . The dose bortezomib lenalidomide increase study best safest amount ( dose ) identify . The participant 's dose study drug depend enter study . - In study cycle 21 day participant begin study medication clinic Cycle 1 Day 1 . Lenalidomide ( capsule ) take daily first 2 week ( Day 1-14 ) . Dexamethasone ( tablet ) take Day 1 , 2 , 4 , 5 , 8 , 9 , 11 12 . Bortezomib give intravenously outpatient treatment clinic Day 1 , 4 , 8 11 . The third week rest period study medication give . - During course study treatment , test procedure perform designated time period . This include ; medical history update , physical/neurological examination , skeletal survey ( x-rays scan ) , blood sample , optional bone marrow aspiration/tissue biopsy , urine sample , 12-lead ECG , MRI/CT scan ( need ) . - It expect study participant receive study treatment 8 cycle ( 168 day ) . If participant completes first 8 cycle study , stable respond disease experience bad side effect , allow continue treatment maintenance schedule , detail protocol , study doctor 's discretion .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosed multiple myeloma base standard diagnostic criterion new International Myeloma Foundation 2003 Diagnostic Criteria Must previously treat prior systemic therapy treatment multiple myeloma Negative serum urine pregnancy test Age 18 year old Karnofsky performance status great equal 60 Greater equal Grade 2 peripheral neuropathy clinical examination within 14 day enrollment Renal insufficiency ( serum creatinine &gt; 2.5 mg/dL ) Evidence mucosal internal bleeding and/or platelet refractory ANC ( absolute neutrophil count ) &lt; 1000 cells/mm3 Hemoglobin &lt; 8.0 g/dL AST ( aspartate aminotransferase ) ALT ( alanine aminotransferase ) great equal 2 x ULN ( upper limit normal ) Concomitant therapy medication include corticosteroid Myocardial infarction within 6 month prior enrollment accord NYHA ( New York Heart Association ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormalities Clinically relevant active infection serious comorbid medical condition Prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical , breast prostate cancer Pregnant breastfeed Serious medical psychiatric illness likely interfere participation study Uncontrolled diabetes mellitus Hypersensitivity acyclovir similar antiviral drug POEMS syndrome Known HIV infection Known active hepatitis B C viral infection Known intolerance steroid therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>newly diagnose multiple myeloma</keyword>
</DOC>